Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2009 2
2010 6
2011 3
2013 1
2015 1
2016 1
2017 2
2019 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
Bain G, Shannon KE, Huang F, Darlington J, Goulet L, Prodanovich P, Ma GL, Santini AM, Stein AJ, Lonergan D, King CD, Calderon I, Lai A, Hutchinson JH, Evans JF. Bain G, et al. Among authors: santini am. J Pharmacol Exp Ther. 2017 Jan;360(1):1-13. doi: 10.1124/jpet.116.237156. Epub 2016 Oct 17. J Pharmacol Exp Ther. 2017. PMID: 27754931
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).
Bain G, King CD, Rewolinski M, Schaab K, Santini AM, Shapiro D, Moran M, van de Wetering de Rooij S, Roffel AF, Schuilenga-Hut P, Milne GL, Lorrain DS, Li Y, Arruda JM, Hutchinson JH, Prasit P, Evans JF. Bain G, et al. Among authors: santini am. Clin Pharmacol Ther. 2010 Apr;87(4):437-44. doi: 10.1038/clpt.2009.301. Epub 2010 Feb 24. Clin Pharmacol Ther. 2010. PMID: 20182424 Clinical Trial.
Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Bain G, King CD, Schaab K, Rewolinski M, Norris V, Ambery C, Bentley J, Yamada M, Santini AM, van de Wetering de Rooij J, Stock N, Zunic J, Hutchinson JH, Evans JF. Bain G, et al. Among authors: santini am. Br J Clin Pharmacol. 2013 Mar;75(3):779-90. doi: 10.1111/j.1365-2125.2012.04386.x. Br J Clin Pharmacol. 2013. PMID: 22803688 Free PMC article. Clinical Trial.
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
Rowbottom MW, Bain G, Calderon I, Lasof T, Lonergan D, Lai A, Huang F, Darlington J, Prodanovich P, Santini AM, King CD, Goulet L, Shannon KE, Ma GL, Nguyen K, MacKenna DA, Evans JF, Hutchinson JH. Rowbottom MW, et al. Among authors: santini am. J Med Chem. 2017 May 25;60(10):4403-4423. doi: 10.1021/acs.jmedchem.7b00345. Epub 2017 May 15. J Med Chem. 2017. PMID: 28471663
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
Swaney JS, Chapman C, Correa LD, Stebbins KJ, Broadhead AR, Bain G, Santini AM, Darlington J, King CD, Baccei CS, Lee C, Parr TA, Roppe JR, Seiders TJ, Ziff J, Prasit P, Hutchinson JH, Evans JF, Lorrain DS. Swaney JS, et al. Among authors: santini am. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700. doi: 10.1124/jpet.110.175901. Epub 2010 Dec 15. J Pharmacol Exp Ther. 2011. PMID: 21159750
16 results